| Patents for A61K 45 - Medicinal preparations containing active ingredients not provided for in groups (115,020) |
|---|
| 11/20/2001 | CA2017851C Micronised biodegradable particles, process for preparing them and the use thereof |
| 11/19/2001 | CA2308994A1 Neuroprotective compounds |
| 11/18/2001 | CA2722134A1 Human monoclonal antibody against a costimulatory signal transduction molecule ailim and pharmaceutical use thereof |
| 11/15/2001 | WO2001086002A2 Compositions, kits, and methods for identification, assessment, prevention, and therapy of psoriasis |
| 11/15/2001 | WO2001085995A2 Identification of neural defects associated with the nucleosom al assembly protein 1l2 gene |
| 11/15/2001 | WO2001085980A2 Enzymatic assays for screening anti-cancer agents |
| 11/15/2001 | WO2001085960A1 Bacterial carboxypeptidase cpg2 variants and their use in gene directed enzyme prodrug therapy |
| 11/15/2001 | WO2001085956A2 Lipid metabolism enzymes |
| 11/15/2001 | WO2001085955A1 Rh116 polypeptides and its fragments and polynucleotides encoding said polypeptides and therapeutic uses |
| 11/15/2001 | WO2001085953A1 Sphingosine kinase and uses thereof |
| 11/15/2001 | WO2001085944A2 Production of adenine nucleotide translocator (ant), novel ant ligands and screening assays therefor |
| 11/15/2001 | WO2001085942A2 Cytoskeleton-associated proteins |
| 11/15/2001 | WO2001085941A2 Myc targets |
| 11/15/2001 | WO2001085938A1 Modified es cells and es cell-specific gene |
| 11/15/2001 | WO2001085937A2 Regulator of g protein signalling (rgs8) |
| 11/15/2001 | WO2001085935A2 Endothelial differentiation gene 6-like g protein coupled receptor |
| 11/15/2001 | WO2001085924A2 MODULATION OF η-SECRETASE ACTIVITY |
| 11/15/2001 | WO2001085912A2 Presenilin enhancers |
| 11/15/2001 | WO2001085797A1 Human igm antibodies with the capability of inducing remyelination, and diagnostic and therapeutic uses thereof particularly in the central nervous system |
| 11/15/2001 | WO2001085790A2 Mammalian cytokine receptor subunit proteins, related reagents and methods |
| 11/15/2001 | WO2001085785A2 Ph domain-interacting protein |
| 11/15/2001 | WO2001085781A2 Repair of nerve damage |
| 11/15/2001 | WO2001085779A2 Protein complexes and assays for screening anti-cancer agents |
| 11/15/2001 | WO2001085762A2 Cancer diagnosis and assays for screening anti-cancer agents |
| 11/15/2001 | WO2001085724A1 Gastrin and cholecystokinin receptor ligands (iii) |
| 11/15/2001 | WO2001085723A1 Gastrin and cholecystokinin receptor ligands (ii) |
| 11/15/2001 | WO2001085704A1 Gastrin and cholecystokinin receptor ligands (iv) |
| 11/15/2001 | WO2001085700A2 Hiv replication inhibiting pyrimidines and triazines |
| 11/15/2001 | WO2001085699A2 Prodrugs of hiv replication inhibiting pyrimidines |
| 11/15/2001 | WO2001085695A1 Tetrahydroisoquinoline analogs useful as growth hormone secretagogues |
| 11/15/2001 | WO2001085694A2 Substituted diamide derivatives useful as motilin antagonists |
| 11/15/2001 | WO2001085664A2 Compounds and methods for regulating bacterial growth and pathogenesis |
| 11/15/2001 | WO2001085345A1 Media milling |
| 11/15/2001 | WO2001085257A2 Opioid antagonist compositions and dosage forms |
| 11/15/2001 | WO2001085256A2 Critical illness neuropathy |
| 11/15/2001 | WO2001085219A2 Identification, diagnosis, and treatment of breast cancer |
| 11/15/2001 | WO2001085206A2 Immunosuppressive compositions comprising an immunophilin-binding compound and a gingkolide compound |
| 11/15/2001 | WO2001085204A2 Therapeutic method and composition utilizing antigen-antibody complexation and presentation by dendritic cells |
| 11/15/2001 | WO2001085203A2 Therapeutic method and composition utilizing antigen-antibody complexation and presentation by dendritic cells |
| 11/15/2001 | WO2001085201A2 Use of il-18 inhibitors for the treatment and/or prevention of atherosclerosis |
| 11/15/2001 | WO2001085199A1 PHARMACEUTICAL COMPOSITION COMPRISING A FACTOR VIIa AND A TFPI INHIBITOR |
| 11/15/2001 | WO2001085198A1 tHARMACEUTICAL COMPOSITION COMPRISING A FACTOR VIIA AND A FACTOR XIII |
| 11/15/2001 | WO2001085196A2 Cxcr4 antagonist treatment of hematopoietic cells |
| 11/15/2001 | WO2001085194A1 Method and composition for the treatment of angiogenesis |
| 11/15/2001 | WO2001085193A2 Method for promoting neovascularization using a tweak agonist and an angiogenic factor |
| 11/15/2001 | WO2001085171A1 Local anesthetic methods and kits |
| 11/15/2001 | WO2001085169A2 R-eliprodil for treating glaucoma |
| 11/15/2001 | WO2001085168A1 Use of compounds having combined dopamine d2, 5-ht1a and alpha adrenoreceptor agonistic action for treating cns disorders |
| 11/15/2001 | WO2001085166A1 Methods for inhibiting proliferation and inducing apoptosis in cancer cells |
| 11/15/2001 | WO2001085165A2 Combination of lipoic acid and c1 donors for the treatment of disorders of the central nervous system |
| 11/15/2001 | WO2001085157A1 Compositions and methods for treatment of proliferative disorders |
| 11/15/2001 | WO2001085155A1 Method and compositions for inhibiting arteriosclerosis |
| 11/15/2001 | WO2001085154A2 Method of treating immune pathologies with low dose estrogen |
| 11/15/2001 | WO2001085153A2 Potentiation of antineoplastic agents using sigma-2 ligands |
| 11/15/2001 | WO2001085152A2 R-eliprodil for treating glaucoma |
| 11/15/2001 | WO2001085150A2 Opioid antagonist containing composition for enchaching the potency or reducing adverse side effects ofopioid agonists |
| 11/15/2001 | WO2001085146A1 Pharmaceutical compounds for treating copd |
| 11/15/2001 | WO2001085145A2 A pharmaceutical composition and method of treatment of diseases of cognitive dysfunction in a mammal |
| 11/15/2001 | WO2001085144A2 Use of substituted acryloyl distamycin derivatives in the treatment of tumors associated with high levels of glutathione |
| 11/15/2001 | WO2001085142A1 Compositions and methods for protecting cells during cancer chemotherapy and radiotherapy |
| 11/15/2001 | WO2001085096A2 Mast cell regulation |
| 11/15/2001 | WO2001085095A2 Chiral fluoroquinolizinone arginine salt forms |
| 11/15/2001 | WO2001084961A2 Preparation for the prevention and/or treatment of vascular disorders |
| 11/15/2001 | WO2001076627A8 Treatment of fungal infections with polyene or beta glucan synthase inhibitor antifungals combined with anti hsp90 antibodies |
| 11/15/2001 | WO2001042794A3 Method for identifying inhibitors of cytokinesis |
| 11/15/2001 | WO2001039761B1 Administration of an alpha-2 adrenergic receptor agonist to enhance cardiopulmonary resuscitation |
| 11/15/2001 | WO2001032878A3 A novel polypeptide hormone phosphatonin |
| 11/15/2001 | WO2001012202A3 Use of chemical chelators as reversal agents for drug-induced neuromuscular block |
| 11/15/2001 | WO2001008672A3 Glucamine compounds for treating hepatitis virus infections |
| 11/15/2001 | WO2001007088A3 Methods for treating therapy-resistant tumors |
| 11/15/2001 | WO2001006756A3 Use of diphenyliodonium for the activation and protection of cytotoxic lymphocytes |
| 11/15/2001 | WO2001002550A3 Cell death related drug targets in yeast and fungi |
| 11/15/2001 | WO2001000187A3 Pharmaceutical composition containing sibutramine and a lipase inhibitor |
| 11/15/2001 | WO2000063379A3 The p2x3 receptor, methods of altering p2x3 receptor activity and uses thereof |
| 11/15/2001 | WO2000055323A9 Differential expression of organellar gene products |
| 11/15/2001 | WO2000053232A9 Matriptase, a serine protease and its applications |
| 11/15/2001 | WO2000026370A9 Adenine nucleotide translocator (ant) fusion proteins and uses thereof |
| 11/15/2001 | US20010041747 S(+) desmethylselegiline and its use to treat immune system dysfunction |
| 11/15/2001 | US20010041746 Reduce side effect; analgesics |
| 11/15/2001 | US20010041732 Use |
| 11/15/2001 | US20010041729 Use of prostaglandin (PGE2) receptor 4 (EP4) selective agonists for the treatment of acute and chronic renal failure |
| 11/15/2001 | US20010041726 Nitrosated and nitrosylated cyclooxygenase-2 inhibitors, compositions and methods of use |
| 11/15/2001 | US20010041723 Using agonists and antagonists of the nicotinergic acetylcholine receptors of insects such as fleas, lice and flies, on humans and animals |
| 11/15/2001 | US20010041722 Compositions containing a substituted indolealkanoic acid and an angiotensin converting enzyme inhibitor |
| 11/15/2001 | US20010041718 Cis-6-(4-fluoro-phenyl)-5-(4-(2-piperidin-1-yl-ethoxy)-phenyl) -5,6,7,8-tetrahydronaphthalene-2-ol, for example, and other estrogen agonists/antagonists to treat rheumatoid arthritis, colon cancer, wounds, cataracts and skin wrinkles |
| 11/15/2001 | US20010041713 Cyclooxygenase-2 (COX-2); administering 2-(2-methylpyrid-5-yl),3-(p-methylsulfonylphenyl),5-chloro-pyridine, or salt, hydrate or N-oxide thereof, alone or in combination with other drugs |
| 11/15/2001 | US20010041706 By administering a CYP3A4 inhibitor and a CYP2C8 inhibitor, CYP3A4 represents 25% of all cytochrome P450's in the human liver and CYP2C8 is the major pathway of paclitaxel inactivation; reduce taxane pharmacokinetic variability |
| 11/15/2001 | US20010041703 Which are growth hormone secretogogues and increase the level of endogenous growth hormone; treating osteoporosis, congestive heart failure, frailty associated with aging, obesity; accelerating bone fracture repair |
| 11/15/2001 | US20010041688 Methods and compositions for the regulation of vasoconstriction |
| 11/15/2001 | US20010041687 Administering an effective amount of a flavone 8-carboxylic acid to a mammal suffering from a vascular or cardiovascular or acute coronary syndromes alone or with thromolytic, anticoagulants, antithrombotic or antiplatelet agents |
| 11/15/2001 | US20010041685 Mucin synthesis inhibitors |
| 11/15/2001 | US20010041681 Therapeutically useful synthetic oligonucleotides |
| 11/15/2001 | US20010041678 Consists of N-chlorophenylcarbamates and N-chlorophenylthiocarbamates along with chemotherapeutic agent; anticancer and antitumor agents |
| 11/15/2001 | US20010041672 Luteinizing hormone releasing hormone analogs or a combination with antiestrogen which is selected from raloxifen, droloxifen, centchroman or derivatives, useful for treating endometrioses and myomas ( gynecological conditions) |
| 11/15/2001 | US20010041668 Selecting compound that is functionally equivalent to a gene product expressed in an embryo's extraembryonic tissue, causing the compound to access the cells to stimulate cells to undergo hematopoiesis and vascular growth |
| 11/15/2001 | US20010041363 Hollow fiber bioreactor; filtration |
| 11/15/2001 | US20010041186 Composition and method for acceleration of wound and burn healing |
| 11/15/2001 | US20010041182 Stable activity antioxidant provitamin such as l-ascorbic acid-2-phosphate and alpha-tocopheryl phosphate |
| 11/15/2001 | US20010041178 Preventing airway mucus production by administration of EGF-R antagonists |
| 11/15/2001 | DE10045904A1 Retard alpha-lipoic acid composition based on cationogenic polymer carrier, especially chitosan, useful as a food supplement, medicament or cosmetic |